ReShape Lifesciences Inc. (RSLS) Stock Analysis

ReShape Lifesciences Inc. (RSLS) Healthcare & Pipeline Overview

ReShape Lifesciences Inc. specializes in innovative medical devices designed to treat obesity and metabolic diseases, positioning itself as a leader in minimally invasive weight management solutions with a diverse product portfolio.

What Is the Investment Thesis for RSLS?

ReShape Lifesciences Inc. presents a unique opportunity in the healthcare sector with its focus on obesity management, a market projected to grow significantly due to rising obesity rates globally. Furthermore, the ongoing development of the ReShape Diabetes Bloc-Stim technology could open new revenue streams in the diabetes treatment space. However, the company faces challenges, including a negative profit margin of -274.5% and reliance on a limited product range, which necessitates successful commercialization of its investigational products. Monitoring the execution of its growth strategies and the regulatory landscape will be critical for investors.

Based on FMP financials and quantitative analysis

RSLS Key Highlights

Market Cap: $0.00B indicating a current lack of market valuation.

• P/E Ratio: -0.06, reflecting losses relative to earnings.
• Profit Margin: -274.5%, highlighting significant operational challenges.
• Gross Margin: 62.4%, indicating potential for profitability if costs are managed effectively.
• Beta: 1.90, suggesting higher volatility compared to the market.

Who Are RSLS's Competitors?

RSLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RSLS's Key Strengths?

Innovative product portfolio addressing a significant health issue.

• Strong gross margin of 62.4%, indicating potential profitability.
• Established brand recognition in the obesity treatment market.
• Diverse offerings including both devices and telehealth services.

What Are RSLS's Weaknesses?

Negative profit margin indicating operational challenges.

• Limited product range may hinder market competitiveness.
• Small employee base of 17 may limit operational capacity.
• Dependence on successful commercialization of investigational products.

What Could Drive RSLS Stock Higher?

Potential commercialization of the ReShape Vest system as clinical trials progress.

• Development of ReShape Diabetes Bloc-Stim technology in preclinical stages.
• Expansion of the ReShapeCare telehealth program into new markets.
• Efforts to increase brand awareness and partnerships with healthcare providers.
• Regulatory submissions for new products expected in the next 12-18 months.

What Are the Key Risks for RSLS?

Financial-distress signal — its Altman Z-Score of -12.12 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles could delay product launches and market entry.
• Financial instability due to negative profit margins and operational losses.
• Increased competition from established players in the obesity treatment market.
• Dependence on a small employee base may limit operational scalability.

What Are the Growth Opportunities for RSLS?

• ReShape Lifesciences Inc. can capitalize on this trend with its innovative product offerings, particularly the ReShape Vest, which is designed to provide a minimally invasive solution for weight loss. By expanding its market presence and enhancing its product portfolio, the company could significantly increase its revenue streams over the next five years.
• Growth opportunity 2: The telehealth sector is rapidly expanding, with the virtual health coaching market expected to grow at a CAGR of 30% through 2025. ReShapeCare, the company's telehealth weight management program, positions ReShape Lifesciences to leverage this trend by offering accessible and effective weight management solutions to a broader audience. As more patients seek remote healthcare options, the potential for increased adoption of ReShapeCare could drive substantial revenue growth.
• Growth opportunity 3: The development of the ReShape Diabetes Bloc-Stim Neuromodulation technology presents a significant opportunity for ReShape Lifesciences Inc. in the diabetes treatment market. With type 2 diabetes affecting over 400 million people worldwide, successful commercialization of this technology could tap into a lucrative market segment. The expected timeline for clinical trials and potential market entry could align with increasing demand for innovative diabetes management solutions over the next five years.
• Growth opportunity 4: Expanding into international markets, particularly in Europe and Asia, offers ReShape Lifesciences Inc. the chance to diversify its revenue streams. With obesity rates rising globally, entering these markets could enhance the company's growth trajectory. Strategic partnerships with local healthcare providers and distributors could facilitate market entry and increase brand recognition, potentially leading to significant sales growth in the coming years.
• Growth opportunity 5: The increasing focus on preventive healthcare and lifestyle management opens avenues for ReShape Lifesciences Inc. to enhance its product offerings. By integrating additional health services and products that complement its existing solutions, the company can create a comprehensive ecosystem for weight management and metabolic disease treatment. This approach could attract a wider customer base and increase patient retention, driving long-term growth.

What Threats Does RSLS Face?

• Intense competition from established medical device companies.
• Regulatory challenges in bringing new products to market.
• Economic downturns impacting healthcare spending.
• Potential patent expirations affecting product exclusivity.

What Are RSLS's Competitive Advantages?

• Innovative product offerings that differentiate from traditional obesity treatments.
• Strong intellectual property portfolio protecting proprietary technologies.
• Established relationships with healthcare providers and institutions.
• Focus on minimally invasive procedures appealing to patient preferences.
• Comprehensive approach combining devices with virtual health coaching.

What Does RSLS Do?

ReShape Lifesciences Inc., incorporated in 2002 and headquartered in San Clemente, California, is a pioneering medical device company that focuses on the management and treatment of obesity and metabolic diseases. Originally known as EnteroMedics Inc., the company rebranded in 2017 to reflect its commitment to providing innovative solutions for weight management. ReShape's product portfolio includes the Lap-Band System, which offers a minimally invasive long-term treatment for severe obesity, as well as more invasive surgical options like gastric bypass and sleeve gastrectomy. A key innovation is the ReShape Vest system, an investigational device designed to facilitate weight loss without the need for cutting or removing parts of the stomach. Additionally, ReShape Lifesciences provides the ReShapeCare virtual health coaching program, a telehealth initiative aimed at supporting healthy lifestyle changes among patients. The company is also developing the ReShape Diabetes Bloc-Stim Neuromodulation technology, currently in preclinical stages, targeting type 2 diabetes mellitus. Another notable product is the Obalon Balloon System, which utilizes a swallowable capsule to assist in weight management. With a presence in the United States, Australia, Europe, and beyond, ReShape aims to address the growing global obesity epidemic through its innovative and comprehensive solutions.

What Products and Services Does RSLS Offer?

• Develops and markets medical devices for obesity management.
• Offers the Lap-Band System for minimally invasive weight loss surgery.
• Provides the ReShape Vest, a novel device for weight loss without surgical removal of stomach tissue.
• Operates ReShapeCare, a virtual health coaching program for weight management.
• Conducts research and development for the ReShape Diabetes Bloc-Stim technology.
• Markets the Obalon Balloon System, a swallowable capsule for weight management.

How Does RSLS Make Money?

• Generates revenue through the sale of medical devices and systems for obesity treatment.
• Offers subscription-based services for the ReShapeCare telehealth program.
• Engages in partnerships for research and development of new technologies.
• Explores licensing agreements for its proprietary technologies.
• Provides training and support services for healthcare providers using its products.

What Industry Does RSLS Operate In?

The medical devices industry, particularly in obesity management, is witnessing robust growth driven by increasing obesity rates and a rising awareness of associated health risks. The global obesity treatment market is projected to expand significantly, with a compound annual growth rate (CAGR) of approximately 10% over the next several years. ReShape Lifesciences Inc. fits into this landscape by offering innovative, minimally invasive solutions that cater to the growing demand for effective weight management options. The competitive landscape includes notable companies such as ATNX, CUTR, EIGRQ, FRES, and GMVD, which also focus on obesity and metabolic disease treatments, making innovation and differentiation crucial for market share.

Who Are RSLS's Key Customers?

• Obese and morbidly obese patients seeking weight loss solutions.
• Healthcare providers and surgeons specializing in obesity treatment.
• Insurance companies looking to cover innovative obesity management solutions.
• Healthcare institutions focusing on metabolic disease treatments.
• Patients enrolled in telehealth programs for weight management.

Company Profile

ReShape Lifesciences Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Clemente, US. The company is led by CEO Paul F. Hickey. RSLS has traded publicly since 2016.

How ReShape Lifesciences Inc. Is Valued

ReShape Lifesciences Inc. carries a market capitalization of $2.34M, placing it in the micro-cap category.

Key Financial Metrics

Its free cash flow yield is -24.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -100.8%, the inverse of the P/E and a quick read on earnings relative to price.

ReShape Lifesciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.12 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project ReShape Lifesciences Inc. revenue of about $300K for fiscal 2026, with EPS near $-0.70.

RSLS Financials

RSLS Latest News

No recent news available for RSLS.

Common Questions About RSLS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources